시장보고서
상품코드
1791751

세계의 뉴클레오티드 시장

Nucleotide

발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 뉴클레오티드 시장은 2030년까지 14억 달러에 이를 전망

2024년에 9억 7,690만 달러로 추정되는 뉴클레오티드 세계 시장은 분석 기간인 2024-2030년 CAGR 6.4%로 성장하여 2030년에는 14억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Deoxy Nucleotides는 CAGR 7.8%를 나타내고, 분석 기간 종료시에는 6억 8,110만 달러에 이를 것으로 예측됩니다. RNA 합성용 뉴클레오티드 부문의 성장률은 분석 기간중 CAGR 4.6%로 추정됩니다.

미국 시장은 2억 5,680만 달러로 추정, 중국은 CAGR 6.1%로 성장 예측

미국의 뉴클레오티드 시장은 2024년에 2억 5,680만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년간 CAGR 6.1%로 2030년까지 2억 2,640만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 6.1%와 5.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.9%를 보일 전망입니다.

세계의 뉴클레오티드 시장 - 주요 동향과 촉진요인 정리

뉴클레오타이드가 영양, 제약, 생명공학에서 전략적 중요성이 커지는 이유는 무엇일까?

DNA와 RNA의 구성요소인 유기분자인 뉴클레오티드는 다양한 산업에서 빠르게 용도가 확대되고 있으며, 기본적인 생화학적 성분에서 고부가가치 기능성 성분으로 변모하고 있습니다. 전통적으로 뉴클레오티드는 세포 대사, 유전정보 저장, 에너지 전달(ATP 등)에 필수적인 역할을 하는 것으로 알려져 왔지만, 현재는 유아 영양, 동물사료에서 의약품, 생명공학에 이르기까지 다양한 분야에서 수요가 증가하고 있습니다. 인간 영양 분야에서는 면역 지원, 위장 발달 등 모유에서 발견되는 기능적 이점을 모방하기 위해 유아용 조제 분유에 뉴클레오티드를 첨가하는 사례가 증가하고 있습니다. 동물 건강 분야에서는 가축 사료에 뉴클레오티드를 첨가하여 장 건강, 성장 성능, 질병 저항성을 향상시킬 수 있습니다. 한편, 제약 산업에서 뉴클레오티드는 항바이러스제 및 항암제 합성에서 전구체 및 중간체로 사용됩니다. 유전자 연구, 진단, 치료, 특히 PCR 키트, mRNA 합성, 올리고뉴클레오타이드 기반 치료에서 뉴클레오타이드의 역할은 코로나19 이후 새로운 모멘텀을 얻고 있습니다. 생명공학 및 생명과학 산업이 빠르게 성장함에 따라 뉴클레오티드는 유전자 치료, 백신 개발, 차세대 염기서열 분석기(NGS) 등 첨단 응용 분야의 기초 원료가 되고 있습니다. 이러한 최종 용도 영역이 계속 진화하는 가운데, 뉴클레오티드는 건강, 과학, 혁신의 교차점에 위치하고 있으며, 그 시장 가치는 범용 화학제품에서 전략적 생명과학 투입물로 이동하고 있습니다.

기술의 발전과 공정의 최적화는 어떻게 제품의 진화를 촉진하고 있는가?

발효 기술, 효소 합성, 바이오프로세스 공학의 발전은 뉴클레오타이드 생산 방법을 재정의하고 수율, 순도, 확장성을 향상시켜 급증하는 시장 수요에 대응하고 있습니다. 효모 및 기타 천연 자원으로부터의 전통적인 추출이 여전히 일반적이지만, 현대 산업 공정은 더 높은 효율성과 지속가능성을 달성하기 위해 미생물 발효 및 효소적 생물 전환을 선호하고 있습니다. 이러한 방법은 생산 비용을 절감할 뿐만 아니라 의약품 및 영양제 응용 분야에서 중요한 뉴클레오타이드의 구성과 농도를 정확하게 제어할 수 있습니다. 또한, 제조업체들은 주사제 및 치료용 제품의 초순도, GMP 준수 뉴클레오티드에 대한 수요 증가에 대응하기 위해 다운스트림 정제 및 결정화 기술에도 투자하고 있습니다. 또한, 맞춤화가 중요한 차별화 요소가 되고 있으며, 유아용 영양제, 스포츠 보충제, 기능성 식품 등에서는 특정 건강 기능에 맞게 맞춤형 뉴클레오티드 블렌드를 처방하고 있습니다. 바이오인포매틱스와 합성생물학의 부상은 뉴클레오티드 아날로그 합성을 위한 새로운 경로를 열어 의약품 개발 및 유전공학에 큰 잠재력을 가져다주고 있습니다. 자동화, 실시간 공정 모니터링, 데이터 기반 최적화가 생산 라인에 점점 더 많이 통합되어 배치 일관성, 규정 준수 및 환경 지속가능성을 강화합니다. 이러한 기술 혁신을 통해 공급업체는 밸류체인을 개선하고, 대량 뉴클레오티드뿐만 아니라 차세대 헬스케어 및 영양 제품에 신속하게 통합할 수 있는 응용 가능하고 기능적으로 강화된 변이체를 제공할 수 있게 되었습니다.

건강이 최우선인 세계 경제에서 뉴클레오타이드의 산업을 넘어선 수요를 촉진하는 것은 무엇인가?

면역 건강, 질병 예방, 생명공학 중심의 기술 혁신에 대한 전 세계의 관심이 높아지면서 뉴클레오타이드의 대응 가능한 시장이 크게 확대되고 있습니다. 소비자 영양 분야에서는 영유아의 발달과 면역에 대한 인식이 높아지면서 뉴클레오티드 블렌드를 포함한 강화 유아용 조제분유에 대한 수요가 증가하고 있습니다. 마찬가지로, 면역력 강화와 피로 회복을 촉진하는 보충제를 찾는 성인들이 식품 및 건강기능식품 브랜드에 뉴클레오티드를 기능성 제품 포트폴리오에 포함시키도록 촉구하고 있습니다. 축산업에서 항생제 사용이 줄어들면서 뉴클레오티드는 가축의 성능 및 질병 저항성을 향상시키기 위한 귀중한 대체재, 특히 가금류, 양돈, 양식업 분야에서 대체재로 활용되고 있습니다. 생명공학 분야에서 PCR 시약, RNA 기반 의약품, 진단 도구에 대한 수요가 폭발적으로 증가함에 따라 뉴클레오티드는 연구소와 제약회사에 필수적인 요소로 자리 잡았습니다. 코로나19 팬데믹은 이러한 추세의 기폭제가 되어 신속 반응 백신 개발 및 진단 테스트 생산에서 뉴클레오티드 빌딩 블록의 전략적 역할을 강화했습니다. 의약품 제조에서는 뉴클레오티드가 합성 의약품 원료, 특히 항바이러스제나 암 치료제의 출발 원료로 사용되는 경우가 증가하고 있습니다. 또한, CRISPR 기술, 유전자 편집, 합성 백신의 새로운 이용 사례는 새로운 상업적 길을 열어가고 있습니다. 전 세계 의료 시스템이 정밀의료, 면역 회복력, 조기 개입에 초점을 맞추고 있는 가운데, 뉴클레오티드는 치료 전략과 예방 의료 제품에 필수적인 요소로 자리 잡고 있습니다. 이러한 산업 전반 수요는 소비자의 건강 의식, 농업의 변화, 생물의학 혁신의 수렴을 반영하고 있으며, 이는 모두 세계 바이오 경제에서 뉴클레오티드의 역할이 견고하고 확대되고 있음을 보여줍니다.

뉴클레오티드 세계 시장 성장 원동력은?

뉴클레오타이드 시장의 성장은 기술 혁신, 최종 용도 진화, 규제 당국의 지원, 소비자 및 산업계의 우선순위 변화와 관련된 여러 요인에 의해 주도되고 있습니다. 첫째, 영유아 영양, 기능성 식품, 동물사료에 대한 적용 확대로 면역, 소화, 건강 전반을 지원하는 뉴클레오티드 강화 제품에 대한 수요가 꾸준히 증가하고 있습니다. 둘째, 의약품 합성, 백신 개발, 유전자 치료에서 바이오 제약 산업의 뉴클레오티드 의존도가 높아지면서, 특히 전 세계 감염병 대책에 따라 시장 수요가 크게 증가하고 있습니다. 셋째, 생명공학과 유전공학의 발전으로 뉴클레오티드는 원료에서 진단약, mRNA 치료제, 올리고뉴클레오티드 의약품, DNA 시퀀싱 기술에 필수적인 구성 요소로 승화되었습니다. 넷째, 전 세계 규제 당국이 식품, 사료, 의약품에 뉴클레오티드를 포함하는 것을 승인하고 있어 제품의 정당성을 높이고 상업적 채택을 가속화하고 있습니다. 다섯째, 제조업체는 환경과 비용 효율성의 목표에 따라 생산물의 품질을 향상시키면서 환경 친화적이고 확장 가능한 생산 기술에 투자하고 있습니다. 여섯째, 항생제를 사용하지 않는 가축 생산에 대한 움직임이 천연 성장 촉진제 및 면역 조절제로서 뉴클레오티드에 대한 수요를 자극하고 있습니다. 또한, 건강기능식품의 전자상거래 성장과 D2C 유통은 지역과 소비자 부문을 넘어 제품 도달 범위를 확장하고 있습니다. 이러한 요인들이 복합적으로 작용하여 뉴클레오타이드 시장은 다분야에 걸쳐 지속 가능한 성장을 가속하고 생명과학, 영양 및 바이오 가공 산업에서 고부가가치 부문으로 확고한 입지를 구축하고 있습니다.

부문

제품(데옥시뉴클레오타이드, RNA 합성용 뉴클레오타이드, 디데옥시뉴클레오타이드, 표지 뉴클레오타이드); 기술(TaqMan 대립유전자 판별 기술, 파이로시퀀싱 기술에 의한 SNP, 유전자 칩 및 마이크로어레이 기술, 기타 기술); 응용(진단 연구 응용, 제약 응용, 식음료 첨가제 응용, 동물 사료 첨가물 응용, 기타 응용).

조사 대상 기업 예

  • Agilent Technologies
  • Ajinomoto Co., Inc.
  • ATTO-TEC GmbH
  • Bioline GmbH
  • Biomatik
  • Bioneer Corporation
  • CJ CheilJedang Corp.
  • Cytiva(formerly part of GE Healthcare)
  • Daesang Corporation
  • Danaher Corporation
  • Eton Bioscience
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH
  • LGC Biosearch Technologies
  • Merck KGaA
  • Revvity(formerly PerkinElmer)
  • Star Lake Bioscience
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

LSH 25.08.21

Global Nucleotide Market to Reach US$1.4 Billion by 2030

The global market for Nucleotide estimated at US$976.9 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Deoxy Nucleotides, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$681.1 Million by the end of the analysis period. Growth in the Nucleotides for RNA Synthesis segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$256.8 Million While China is Forecast to Grow at 6.1% CAGR

The Nucleotide market in the U.S. is estimated at US$256.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$226.4 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Nucleotide Market - Key Trends & Drivers Summarized

Why Are Nucleotides Gaining Strategic Importance Across Nutrition, Pharmaceuticals, and Biotech?

Nucleotides-organic molecules that serve as the building blocks of DNA and RNA-are finding rapidly expanding applications across a variety of industries, transforming them from basic biochemical components into high-value functional ingredients. Traditionally known for their essential role in cellular metabolism, genetic information storage, and energy transfer (e.g., ATP), nucleotides are now in high demand in sectors ranging from infant nutrition and animal feed to pharmaceuticals and biotechnology. In human nutrition, nucleotides are increasingly added to infant formula to mimic the functional benefits found in breast milk, such as enhanced immune support and gastrointestinal development. In animal health, nucleotide supplementation in livestock feed improves gut health, growth performance, and disease resistance-especially in antibiotic-free production systems. Meanwhile, in the pharmaceutical industry, nucleotides are used as precursors or intermediates in the synthesis of antiviral and anticancer drugs. Their role in genetic research, diagnostics, and therapeutics, particularly in PCR kits, mRNA synthesis, and oligonucleotide-based treatments, has gained new momentum post-COVID-19. With biotech and life sciences industries expanding rapidly, nucleotides are becoming a foundational raw material in advanced applications such as gene therapy, vaccine development, and next-generation sequencing (NGS). As these end-use domains continue to evolve, nucleotides are positioned at the intersection of health, science, and innovation-shifting their market value from commodity chemicals to strategic bioscience inputs.

How Are Technological Advancements and Process Optimization Driving Product Evolution?

Advancements in fermentation technology, enzymatic synthesis, and bioprocess engineering are redefining how nucleotides are produced, improving yield, purity, and scalability to meet surging market demand. While traditional extraction from yeast or other natural sources remains common, modern industrial processes now favor microbial fermentation and enzymatic bioconversion for higher efficiency and sustainability. These methods not only reduce production costs but also allow for precise control over nucleotide composition and concentration-critical in pharmaceutical and nutritional applications. Manufacturers are also investing in downstream purification and crystallization technologies to meet the growing need for ultra-pure, GMP-compliant nucleotides in injectable and therapeutic products. Further, customization is becoming a key differentiator, with tailored nucleotide blends being formulated for specific health functions in infant nutrition, sports supplements, and functional foods. The rise of bioinformatics and synthetic biology is also unlocking novel pathways for nucleotide analog synthesis, which holds significant promise in drug development and genetic engineering. Automation, real-time process monitoring, and data-driven optimization are increasingly being integrated into production lines, enhancing batch consistency, regulatory compliance, and environmental sustainability. These innovations are enabling suppliers to move up the value chain-offering not just bulk nucleotides, but application-ready, functionally enhanced variants that can be quickly integrated into next-gen healthcare and nutrition products.

What’s Fueling Cross-Industry Demand for Nucleotides in a Health-First Global Economy?

The growing global emphasis on immune health, disease prevention, and biotechnology-driven innovation is significantly expanding the addressable market for nucleotides. In the consumer nutrition sector, increased awareness of early-life development and immunity is driving demand for fortified infant formulas containing nucleotide blends. Similarly, adults seeking immune-supporting or recovery-enhancing supplements are pushing food and nutraceutical brands to include nucleotides in functional product portfolios. The shift away from antibiotics in animal agriculture has made nucleotides a valuable alternative for improving livestock performance and disease resistance-especially in poultry, swine, and aquaculture sectors. In biotechnology, the explosion in demand for PCR reagents, RNA-based drugs, and diagnostic tools has made nucleotides indispensable to research labs and pharmaceutical manufacturers alike. The COVID-19 pandemic acted as a catalyst for this trend, reinforcing the strategic role of nucleotide building blocks in rapid-response vaccine development and diagnostic test production. In pharmaceutical manufacturing, nucleotides are increasingly used as starting materials for synthetic drug APIs, especially antivirals and oncology drugs. Additionally, emerging use cases in CRISPR technologies, genetic editing, and synthetic vaccines are opening new commercial pathways. As healthcare systems worldwide focus on precision medicine, immune resilience, and early intervention, nucleotides are becoming integral to therapeutic strategies and preventive health products. This cross-industry demand reflects a convergence of consumer health consciousness, agricultural transformation, and biomedical innovation-all pointing toward a robust and expanding role for nucleotides in the global bioeconomy.

What’s Driving the Growth of the Global Nucleotide Market?

The growth in the nucleotide market is driven by several factors tied to technological innovation, evolving end-use applications, regulatory support, and shifts in consumer and industrial priorities. First, expanding applications in infant nutrition, functional foods, and animal feed are creating consistent demand for nucleotide-fortified products that support immunity, digestion, and overall wellness. Second, the biopharmaceutical industry's rising reliance on nucleotides for drug synthesis, vaccine development, and gene therapy is significantly boosting market demand-particularly in the wake of global infectious disease preparedness initiatives. Third, advancements in biotechnology and genetic engineering have elevated nucleotides from raw materials to essential building blocks in diagnostics, mRNA therapeutics, oligonucleotide drugs, and DNA sequencing technologies. Fourth, regulatory authorities across the globe are increasingly approving nucleotide inclusion in food, feed, and pharma formulations, enhancing the product's legitimacy and accelerating commercial adoption. Fifth, manufacturers are investing in green, scalable production technologies that improve output quality while aligning with environmental and cost-efficiency goals. Sixth, the move toward antibiotic-free livestock production is stimulating demand for nucleotides as a natural growth enhancer and immune modulator. Furthermore, e-commerce growth and D2C distribution in nutraceuticals are expanding product reach across geographies and consumer segments. Together, these factors are driving sustained, multi-sectoral growth in the nucleotide market, firmly positioning it as a high-value segment within the life sciences, nutrition, and bioprocessing industries.

SCOPE OF STUDY:

The report analyzes the Nucleotide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides, Labelled Nucleotides); Technology (TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology, Other Technologies); Application (Diagnostics Research Application, Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Agilent Technologies
  • Ajinomoto Co., Inc.
  • ATTO-TEC GmbH
  • Bioline GmbH
  • Biomatik
  • Bioneer Corporation
  • CJ CheilJedang Corp.
  • Cytiva (formerly part of GE Healthcare)
  • Daesang Corporation
  • Danaher Corporation
  • Eton Bioscience
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH
  • LGC Biosearch Technologies
  • Merck KGaA
  • Revvity (formerly PerkinElmer)
  • Star Lake Bioscience
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Nucleotide - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Functional Ingredients in Health and Nutrition Throws the Spotlight on Nucleotide Applications
    • Expansion of Infant Formula Fortification Strengthens the Business Case for Nutritional-Grade Nucleotides
    • Rising Use of Nucleotides in Animal Feed Propels Growth in Antibiotic-Free Livestock Production
    • Here's How Biopharmaceutical Advancements Are Expanding the Addressable Market Opportunity for Pharmaceutical-Grade Nucleotides
    • Increased Adoption in mRNA and Gene Therapy Manufacturing Drives Demand for High-Purity Nucleotide Inputs
    • Surging Investment in Molecular Diagnostics and PCR Technologies Accelerates Nucleotide Consumption in Life Sciences
    • Evolving Role of Nucleotides in Immunity and Gut Health Supplements Spurs Innovation in Nutraceutical Applications
    • Biotech-Driven Production Methods and Fermentation Technology Strengthen Cost-Efficiency and Product Scalability
    • Supply Chain Diversification and Regional Manufacturing Capabilities Expand Access in Emerging Markets
    • Rising Preference for Clean-Label, Allergen-Free, and Sustainable Ingredients Fuels Demand for Bio-Based Nucleotides
    • Integration into Functional Beverages and Sports Nutrition Broadens Consumer-Centric Product Development
    • Next-Generation Sequencing (NGS) and Synthetic Biology Innovations Generate Long-Term Demand for Specialty Nucleotides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nucleotide Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nucleotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nucleotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Deoxy Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Deoxy Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Nucleotides for RNA Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Nucleotides for RNA Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dideoxynucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Dideoxynucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Labelled Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Labelled Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceuticals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceuticals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Food & Beverage Additives Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Food & Beverage Additives Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Animal Feed Additives Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Animal Feed Additives Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Diagnostics Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for TaqMan Allelic Discrimination Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for TaqMan Allelic Discrimination Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for SNP By Pyrosequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for SNP By Pyrosequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Gene Chips & Microarrays Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Gene Chips & Microarrays Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Nucleotide by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Nucleotide by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제